Directors
Robert W. Rieder, MBA
Executive Chairman
Mr. Rieder is Cardiome’s Executive Chairman of the Board of Directors. He served as Cardiome's Chief Executive Officer from joining Cardiome in April 1998 until August 2009. He was appointed Chairman of the Board in March 2007 and assumed the role of Executive Chairman in August 2009. Mr. Rieder has extensive experience in venture capital and in operational management. Prior to joining Cardiome, Mr. Rieder was Vice-President at MDS Ventures Pacific Inc., the Vancouver-based affiliate of MDS Capital Corp., and has served as a director for nine public and private technology companies. Mr. Rieder has also acted as Chief Operating Officer for DBA Telecom Inc., and CEO for Synapse Technologies Inc. Mr. Rieder received his MBA from the University of Western Ontario.
Douglas G. Janzen
President, Chief Executive Officer & Director
Mr. Janzen is Cardiome’s President and Chief Executive Officer, and serves on Cardiome's Board of Directors. Mr. Janzen manages all of Cardiome’s business activities, including capital markets, commercial development, partnering, licensing and other strategic transactions. Mr. Janzen joined Cardiome in January 2003 as Chief Financial Officer, and served as President and Chief Business Officer from March 2006 to August 2009. He has been instrumental to the advancement of Cardiome’s corporate development and the strengthening of its financial position. Prior to joining Cardiome, Mr. Janzen served as Managing Director, Health Sciences and Partner at Sprott Securities, Inc., a Toronto-based investment bank.
Richard M. Glickman (3)
Lead Independent Director
Mr. Glickman was the co-founder, Chairman and Chief Executive Officer of Aspreva Pharmaceuticals Corporation. Prior to establishing Aspreva, Mr. Glickman was the co-founder and Chief Executive Officer of Stressgen Biotechnologies Corporation. Since 2000, Mr. Glickman has served as the Chairman of the board of Vigil Health Solutions Inc., a healthcare services company. Mr. Glickman was also the founder and director of Ontario Molecular Diagnostics, a diagnostic facility that evolved into the largest molecular diagnostic laboratory in Canada. He co-founded Probtec Corporation, a rational drug design and molecular genetics firm, where he established and introduced the first licensed DNA-based forensic and paternity testing services in Canada. He has served on numerous biotechnology boards including roles as Chairman of Life Sciences British Columbia (formerly the British Columbia Biotechnology Alliance), Director of the Canadian Genetic Disease Network and as a member of the federal government’s National Biotechnology Advisory Committee. Mr. Glickman received the Ernst & Young Entrepreneur of the Year 2004 Award for the Pacific Region Life Sciences Group and has received both Canada’s and British Columbia’s Top 40 Under 40 Award for Entrepreneurs.
Jackie M. Clegg (1)(2)
Director
Ms. Jackie Clegg currently serves as a Managing Partner of Clegg International Consultants, LLC. Ms. Clegg is a member of the board of directors of Javelin Pharmaceuticals, Inc., the Chicago Mercantile Exchange and Brookdale Senior Living. She is also on the board of Blockbuster Inc., where she serves as the Chair of the Corporate Governance Committee. She has served as the chair of special committees for divestiture, mergers and acquisitions. Previously, Ms. Clegg served in the U.S. Government. She served as Vice Chair of the Export-Import Bank of the U.S. (Ex-ImBank). Prior to joining Ex-ImBank, she served as a staff member on the U.S. Senate Committee on Banking International Finance Subcommittee and as an associate staff member to the U.S. Senate Committee on Appropriations.
William L. Hunter, M.D. (2)(3)
Director
Dr. Hunter is a co-founder of Angiotech Pharmaceuticals, Inc., and currently serves as President and Chief Executive Officer of the company. He has led Angiotech through significant corporate milestones from its initial rounds of private and public financings, to product commercialization and profitability. Active in a variety of business and scientific organizations, Dr. Hunter serves as the chair of the board for Neuromed Pharmaceuticals Ltd. He is an advisory board member for the Biotechnology MBA Program at the University of Western Ontario’s Ivey School of Business.
Peter W. Roberts, FCA, CPA (Illinois) (1)(2)
Director
Mr. Roberts retired as Chief Financial Officer and Corporate Secretary of Sierra Wireless, Inc. in March 2004. He served in this role from January 1999 until retirement, and was responsible for taking the company public on the Toronto Stock Exchange in May 1999 and a follow-on financing on NASDAQ in May 2000. Prior to joining Sierra Wireless, Inc., Mr. Roberts held senior financial roles over a fifteen-year period with Service Corporation IJK plc, The Loewen Group Inc., The Overwaitea and Save-On Foods Chain and Sydney Development Corporation. Mr. Roberts is a graduate of Touche Ross, and practiced a decade in public accounting. He holds professional accounting designations in Canada, the United States, and the United Kingdom. In June 2007, Mr. Roberts completed his term as President of the Institute of Chartered Accountants of British Columbia. Mr. Roberts is a member of the Risk Management and Governance Board of the Canadian Institute of Chartered Accountants, and is a graduate of the Institute of Corporate Directors.
Harold H. Shlevin, Ph.D. (1)(2)(3)
Director
Dr. Shlevin is Head of Operations for Altea Therapeutics Corporation, an advanced drug delivery company focused on the delivery of therapeutic levels of water soluble biotherapeutics and small drugs through the skin. He joined Altea in October 2008, and is responsible for pharmaceutical research and development, clinical research, regulatory affairs, engineering, clinical and commercial manufacturing, quality assurance, information technology, facility operations and finance. Prior to this, Mr. Shlevin was the President & CEO of Tikvah Therapeutics, Inc., a pharmaceutical enterprise focused on late stage development of neuroscience therapeutics and was previously the Global Senior Vice President, and a member of the boards of Solvay Pharmaceutical, SA and Solvay Pharmaceuticals Inc., Solvay Pharmaceuticals, Inc. (USA), Chairman of the Board of its subsidiary Unimed Pharmaceuticals, Inc., and a member of the board of Solvay Draka, a specialty plastic company with medical device products. Dr. Shlevin has over twenty five years of diverse healthcare business related and global management experience. His direct skills and experience span functions from R&D through commercial operations, including many international roles. His past industry experience includes leadership roles at G.D. Searle and Co., Revlon Health Care Group, Ciba Geigy Corporation, Bausch and Lomb Pharmaceuticals, and he was a founder of Ciba Vision Ophthalmics. Dr. Shlevin’s experience related to his responsibilities as an audit committee member include his tenure as CEO of Solvay and as Senior Vice President where he was regularly involved in assessments and analysis of financial statements and projections and acquisitions of companies and of products. Dr. Shlevin has also taken courses in financial strategies.
(1) Member of our Audit Committee
(2) Member of our Corporate Governance & Nomination Committee
(3) Member of our Compensation Committee